Answer
Palivizumab is a humanised monoclonal antibody that binds the A antigenic site of the RSV fusion protein, neutralising the virus and inhibiting fusion in both RSV subtype A and B strains.
Sources for this answer
- Synagis 50 mg/0.5 ml solution for injectionAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 5Document updated
Sources checked